Interleukin-4 and breast cancer

Breast Cancer

Volumn 7, Issue 3, 2000, Pages 181-186

  Nagai, Shigenori ^a   Toi, Masakazu ^a  

^a TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

Author keywords

Breast cancer; IL 4

Indexed keywords

ESTROGEN; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR;

APOPTOSIS; BREAST TUMOR; CELL CULTURE; DRUG EFFECT; ENZYMOLOGY; HUMAN; IMMUNOLOGY; LYMPHOCYTE; PHYSIOLOGY; REVIEW; TH2 CELL; TREATMENT OUTCOME;

APOPTOSIS; BREAST NEOPLASMS; ESTROGENS; HUMANS; INTERLEUKIN-4; LYMPHOCYTES; RECEPTORS, INTERLEUKIN-4; TH2 CELLS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 0034565064     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/BF02967457     Document Type: Review

References (57)

1. Howad M, Farrar J, Hilfiker M, et al: Identification of a T cell-derived B cell stimulatory factor distinct from IL-2.J Exp Med 155:914-923, 1982. (Pubitemid 12187863)
2. Yokota T, Arai N, de Vries J, et al: Molecular biology of interleukin-4 and interleukin-5 genes and biology of their products that stimulate B cells, T cells and haematopoietic cells. Immuno Rev 102:137-138, 1988.
3. Coffman RL. Seymour B, Lebman DA, et al: The role of helper T cell products in mouse B cell differentiation and isotype regulation. Immuno Rev 102:5-28, 1988. (Pubitemid 18095718)
4. Snpper CM, Finkelman FD, Paul WE: Regulation of IgG1 and IgE production by interleukin 4. Immunol Rev 102:29-56, 1988.
5. Noma Y, Sidras P, Naito T, et al: Cloning for cDNA encoding the murine IgG 1 induction factor by a novel strategy using SP6 promoter. Nature 319:640-644, 1986.
6. Mosmann TR, Coffman RL: TH1 and TH2 cells: difference patterns of lymphokine secretion lead to different functional properties. Ann Rev Immmunol 7 :145-173, 1989. (Pubitemid 19138011)
7. Paliard X, De Waal MR, Yssel H, et al: Simultaneous production of IL-2, IL-4 and IFN-gamma by activated human CD+and CD+T cell clones. J Immunol 141: 849-855, 1988.
8. Lewis DB, Prickett KS, Larsen Aet al: Restricted production of interleukin-4 by activated human T cells. Proc Natl Acad Sci USA 85:9743-9747, 1988. (Pubitemid 19027201)
9. van der Heijden FL, Wierenga EA, Bos JD, et al: High frequency of IL-4 producing CD4 + allergen-specific T lymphocytes in atopic dermatitis lesional skin. J Invest Dermatol 97:389-394, 1991.
10. Banchereau J: Interleukin 4. Nucl Med Biol 17:619-623, 1990. (Pubitemid 20343766)
11. Lownthal JW, Castle BE, Christiansen J, et al: Expression of high affinity receptors for murine interleukin 4(BSF-1) on haematopoietic and nonhaematopoietic cells. J Immunoll 40:456-464, 1988.
12. Park LS, Friend D, Sassenfeld HM, et al: Characterization of the high affinity cell surface receptor for murine B cell stimulatory factor-1. Proc Natl Acad Sci USA 84:1669-1673, 1987.
13. Cabrillat H, Galizzi JP, Djossou O, et al: High affinity binding of human interleukin 4 to cell lines. Biochem Biophys Res Commun. 1 49:995-1001, 1987. (Pubitemid 18024658)
14. Idzerda RL, March CJ, Mosley B, et al: Human interleukin 4 receptor confers biological responsiveness and defines a novel receptor superfamily. J Exp Med 171:861-873, 1990. (Pubitemid 20088987)
15. Galizzi J-P, Zuber CE, Harada N, et al: Molecular cloning of a cDNA encoding the human IL-4 receptor. Int Immunol 2:669-675, 1990. (Pubitemid 20232466)
16. Bazan J F: A novel family of growth factor receptors: a common binding domain in the growth hormone, prolactin, erythropoietin and IL-6 receptors and the p75IL-2 receptor beta-chain. Biochemical and Bilphys Res Commun. 164:788-795, 1989. (Pubitemid 19280337)
17. Topp MS, Koenigsmann M, Anthony M, et al: Rocombinant human interleukin-4 inhibits growth of some human lung tumor cell lines in vitro and in vivo. Blood 82:2837-2844, 1993. (Pubitemid 23318092)
18. Obiri NI, Siegel JP, Varricchio F, et al: Expression of high-affinity IL-4 receptors on human melanoma, ovarian and breast carcinoma cells. Clin Exp Immunol 85:148-155, 1994. (Pubitemid 24207118)
19. Obiri NI, Hillman GG, Haas GP, et al:Expression of high-affinity interleukin-4 receptors on human renal cell carcinoma cells and inhibition of tumor cell growth in vitro by interleukin-4. J Clin Invest 91:88-93, 1993. (Pubitemid 23037257)
20. Varricchio F, Obiri NI, Haas GP, et al: Immunostaining of interleukin-4 receptors on human renal cell carcinoma. Lympyokine Cytokine Res 12:465-469, 1993. (Pubitemid 24007552)
21. Toi M, Bicknell R, Harris AL: Inhibition of colon and breast carcinoma cell growth by interleukin-4. Cancer Res 52:275-279, 1992.
22. Mat I, Larche M, Melcher D: Tumor associated upregulation of IL-4 receptor complex. Br J Cancer. 62 (supple x) :96-98, 1990. (Pubitemid 20226494)
23. Kaklamanis L, Koukourakis. MI, Leek R: Loss of interleukin-4 receptor-associated molecule gp200- MR6 in human breast cancer; Prognostic significance. Br J Cancer 74:1627-1631, 1996. (Pubitemid 26386092)
24. Tubly A, Luqmani YA, Shousha S, et al: Differential expression of gp200-MR6 molecule in benign hyperplasia and down-regulation in invasive carcinoma of the breast. Br J Cancer 74:1005-1011, 1996. (Pubitemid 26333898)
25. Jung T, Bews JP, Enssle KH, et al: Detection of and discrimination between total and free human interleukin 4 and free soluble interleukin 4 receptor by ELISA. J Immunol Method 217:41-50, 1998. (Pubitemid 28449027)
26. Jung T, Wagner K, Neumann C, et al: Enhancement of human IL-4 activity by soluble IL-4 receptors in vitro. Eur J Immnol 29:864-871, 1999. (Pubitemid 29119065)
27. Jung T, Schrader N, Hellwing M, et al: Soluble human interleukin 4 receptor is produced by activated T cells under the control of metalloproteinases. Int Arch Allergy Immunol 119:23-30, 1999. (Pubitemid 29204579)
28. Zlotnick A, Ransom J, Frank G, et al: Interleukin 4 is a growth factor for activated thymocytes: Possible role in T cell ontogeny. Proc Natl Acad Sci USA 84: 3856-3860, 1987. (Pubitemid 17088378)
29. Spits H, Yssel H, Paliard X, et al: IL-4 inhibits IL-2 mediated induction of human lymphokine-activated killer cells, but not the generation of antigen specific cytotoxic T lymhocytes in mixed lymphocyte cultures.J Immunoll 41:29-36, 1988.
30. Brown M, Hu-Li J, Paul WE: IL-4/B cell stimulatory factor-1 stimulates T cell growth by an IL-2 independent mechanism. J Immunoll 41:504-511, 1988.
31. Widmer MB, Grabstein KH: Regulation of cytolytic T lymphocytes generation by B cell stimulatory factors. Nature 326:795-798, 1987. (Pubitemid 17057798)
32. Lee F, Yokota T, Otsuka T, et al: Isolation and characterization of a mouse interleukin cDNA clone that express B-cell stimulatory factor 1 activities and Tcell and mast-cell stimulating activities. Proc Natl Acad Sci USA 83:2061-2065, 1986. (Pubitemid 16020835)
33. Paul WE, Ohara J: B-cell sfimulatory factor-1/intefleukin 4. Ann Rev Immunol 5:429-459, 1987.
34. Santin AD, Ioli GR, Hiserodt JC, et al: Development and characterization of an IL-4 secreting human ovarian carcinoma cell line. Gynecol Oncol 58:230-239, 1995.
35. Golumbek PT, Lazenby AJ, Levitsky HI, et al: Treatment of established renal cancer by tumor cells engineered to secrete interleukin 4. Science 254:713-716, 1991. (Pubitemid 21917394)
36. Tepper RI, Pittengale PK, Leder P: Murine interleukin4 displays potent anti-tumor activity in vivo. Cell 57:503-512, 1989. (Pubitemid 19126283)
37. Blais Y. Gingras S. Haagensen DE, et al: Interleukin-4 interlelukin-13 inhibit estrogen-induced breast cancer cell proliferation and stimulate GCDFP-15 expression in human breast cancer cells. Mol Cell Endocrinol 121; 11-18, 1996. (Pubitemid 26268048)
38. Topp MS, Papadimitriou CA, Eitelbach F, et al: Recombinant human interleukin 4 has antiproliferative activity on human tumor cell lines derived from epithelial and nonepithelial histologies. Cancer Res, 55:2173-2176, 1995.
39. Cressent M, Pidoux E, Cohen R, et al: Interleukin-2 and interleukin-4 display potent antitumor activity on rat medullary thyroid carcinoma cells. Euro J Cancer 31A:2379-2384, 1995. (Pubitemid 26050583)
40. Klara T, Bharat BA: Interleukin4 potentiates the antiproliferative effect of tumor necrosis factor on various tumor cell lines. Cancer Res 51:4266-4270, 1991.
41. Gooch JL, Lee AV, Yee D: Interleukin4 inhibit growth and induce apoptosis in human breast cancer cells. Cancer Res 58:4199-4205, 1998. (Pubitemid 28440580)
42. Blais Y, Zhao C, Huber M, et al: Growth-independent induction of spermidine transport by IL4 and IL-13 in human cancer cells. Int J Cancer 67:532-538, 1996. (Pubitemid 26274111)
43. Pericle F, Giovarelli M, Colombo MP: An efficient Th2-type memory follows CD8+lymphocyte-deriven and eosinophil-mediated rejection of a spontaneous mammary adenocarcinoma engineered to release IL- 4.J Immunoll 53:5659-5673, 1994. (Pubitemid 24377702)
44. Allione A, Consalvo M, Nanni P, et al: Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with IL-2, IL-4, IL6, IL-7, IL-10, tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, and gamma-interferon gene or admixed with conventional adjuvants. Cancer Res 54:6022-6026, 1994.
45. Musiani P, Allione A, Modica A, et al: Role of neutrophils and lymphocytes in inhibition of a mouse mammary adenocarcinoma engineered to release IL- 2, IL-4, IL-7, ILl0. IFN-alpha, IFN-gamma, and TNFalpha. Lab Inves 74: 146-157, 1996.
46. Maeda T, Matsubara H, Sugaya M: Loss of tumorigenecity of human breast cancer cells engineer to produce IL-2, IL-4 or GM-CSF in nude mice. Int J Oncol 15:943-7, 1999.
47. Pacor S, Gagliardi R, Spessotto P: Paracrine effects of IL-4 transfection on TS/A adenocarcinoma cells mediate reduced in vivo growth. Pathol Oncol Res 5: 110-16, 1999. (Pubitemid 29352600)
48. Butcher EC: Leukocyte-endothelial cell recognition: three or more steps to specificity and diversity. Cell 67:1033-1036, 1991. (Pubitemid 121001517)
49. Schleimer RP, Sterbinsky SA, Kaiser J, et al: IL-4 induces adherence of human eosinophils and basophils but not neutrophils to endothelium. J Immunoll 48:1086-1092, 1992.
50. Volpert OV, Fong T, Koch AE, et al: Inhibition of angiogenesis by intefleukin 4. J Exp Med 1 88:1039-1046, 1998.
51. Saleh M, Davis ID, Wilks AF: The paracrine role of tumor-derived mIL-4 on tumor-associated endothelium. Int J Cancer 72:664-672, 1997. (Pubitemid 27356170)
52. Turgeon C, Gingras S, Carriere MC, et al: Regulation of sex steroid formation by interleukin 4 and interleukin 6 in breast cancer cells. J Steroid Mole Biol 65:151-162, 1998. (Pubitemid 28335601)
53. Gingras S, Moriggl R, Groner B, et al: Induction of 3 .fl -hydroxysteroid dehydrogenase/delta5-delta4 lsomerase type 1 gene transcription in human breast cancer cell lines and in normal mammary epithelial cells by interleukin-4 and inerleukin-13. Mol Endocrinol 13:66-81, 1999. (Pubitemid 29022280)
54. Whitehead RP, Unger JM, Goodwin JW, et al: Phase II trial of recombinant human inteleukin 4 in patients with disseminated malignant melnoma; A South west Oncology Group study. J Immunol 21:440-446, 1998. (Pubitemid 28493715)
55. Vokes EE, Figlin R, Hochster H: A phase II study of recombinant human interleukin 4 for advanced or recurrent non-small cell lung cancer. CaneerJ Sei Am 4:46-51, 1998.
56. Stadler WM, Rybak ME, Vogelzang NJ: A phase II study of subcutaneous recombinant human interleukin 4 in metastatic renal cell carcinoma. Cancer 76:1629-1633, 1995.
57. Margolin K, Aronson FR, Sznol M, et al: Phase II studies of recombinant human interleukin 4 in advanced renal cancer and malignant melanoma. J Immunolther Emphasis Tumor Immunol 15:147-53, 1994. (Pubitemid 24047548)